Board Appointment
Harmesh Suniara appointed as Non-executive Director; Lombard Odier holds 28.56% of shares.
Select text to share a quote on X · sign in to keep highlights & notes in your FUM notes
Futura Medical plc (AIM: FUM), the consumer healthcare company behind Eroxon®, that specialises in the development and global commercialisation of innovative and clinically proven sexual health products, is pleased to announce the appointment of Harmesh Suniara to the Board as a Non-executive Director, with immediate effect
Harmesh has over 17 years' experience of working in investment management, with a particular focus on UK small and mid-cap equities. Since 2017 he has worked as a Portfolio Manager at Lombard Odier Asset Management (Europe) Limited, and from 2007, he was an Investment Manager at Henderson Volantis Capital and Gartmore Investment Management.
Funds or accounts managed on a discretionary basis by Lombard Odier Asset Management (Europe) Limited hold in aggregate 86,781,198 ordinary shares of Futura Medical, representing 28.56% of Futura Medical's issued share capital.
Jeff Needham, Chairman of Futura, commented:
"I am delighted to welcome Harmesh to the Board of Futura. We look forward to working with him as we continue our journey of meeting the unmet demand for sexual health products and take advantages of the opportunities available to us."
The following disclosures in relation to the appointment of Harmesh Kumar Suniara, aged 54, are required pursuant to Schedule 2(g) of the AIM Rules for Companies:
| Current | Past 5 years |
C4X Discovery Holdings Limited
IQE Plc
Actual Experience Plc
Harmesh Suniara was a Director at Actual Experience Plc, which entered administration on 14 November 2023.
No further information is required to be disclosed pursuant to AIM Rule 17 and Schedule 2(g) of the AIM Rules for Companies.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.